ENDRA Life Sciences Secures $3.8M Private Placement at Premium to Market, Averting Nasdaq Delisting
Summary
ENDRA Life Sciences secured a $3.8 million private placement at a premium to its current stock price, which is expected to resolve its Nasdaq delisting issue and provide crucial working capital.
Key Events
-
Secures $3.8 Million Private Placement
The company entered into a securities purchase agreement to sell 578,387 shares of common stock (or prefunded warrants) and warrants to purchase up to 1,156,774 shares of common stock, generating approximately $3.8 million in gross proceeds.
-
Offering Priced at Premium to Market
The combined purchase price for the shares/prefunded warrants and accompanying common warrants was $6.57 per unit, significantly above the current stock price of $5.20.
-
Addresses Nasdaq Delisting Threat
The capital raise is expected to increase the company's stockholders' equity above the $2.5 million Nasdaq minimum, potentially resolving the delisting notice received on April 20, 2026.
-
Investor Protection and Influence
A side letter agreement includes a repayment obligation if strategic alternatives are not pursued, a requirement to maintain a segregated cash balance, and grants the investor a board observer right.
Analysis
This $3.8 million private placement is a critical lifeline for ENDRA Life Sciences, which was facing a Nasdaq delisting due to insufficient stockholders' equity and had recently withdrawn a previous offering. The financing, priced at $6.57 per unit (a premium to the current market price of $5.20), includes common stock, prefunded warrants, and common warrants. While highly dilutive, this capital infusion is expected to bring the company back into compliance with Nasdaq listing rules, providing immediate stability and a path forward after a period of significant financial distress and a going concern warning. The investor also gains a board observer right and protection via a side letter agreement requiring repayment if a strategic alternative is not pursued.
At the time of this filing, NDRA was trading at $5.20 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $6.8M. The 52-week trading range was $2.92 to $11.96. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.